Abstract
Bladder cancer arises from bladder urothelium and is localized in a closed cavity, which is readily reached transurethrally. Currently, the patients with superficial bladder cancer undergo transurethral resection followed by intravesical administration of immuno-reactive agents Bacillus Calmette-Guerin or anti-cancer drugs including mitomycin-C and adriamycin. These locally administrated agents can come into contact with cancer cells at high concentration for enough time in the closed cavity. It may be an ideal treatment model in which local drug delivery can maximize the anti-cancerous effect and minimize the side effect to vital organs outside the bladder.
In this review, we describe the current intravesical therapy as well as a pre-clinical and clinical trial of novel drugs and gene therapy. Moreover, we introduce our investigative therapy using small interfering RNA.
